Clinical Trials

In March 2017, Cyprium entered into a Cooperative Research and Development Agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH), to advance the clinical development of CUTX-101 (Copper Histidinate injection) for the treatment of Menkes disease.

Information about the ongoing Phase 3 clinical study of Copper Histidinate can be found at, or at the link below:

CUTX-101 Copper Histidinate (NCT00811785):